PDGFRA signaling actively remodels the glioma microenvironment, contributing to vascular abnormalities (e.g., via the PDGFRA-Endocan-MYC axis), metabolic reprogramming that impairs T cell function, and immune cell polarization, all of which restrict anti-tumor immunity. The gene discussed is ESM1; the disease is glioma.